Want to see KR:069620 full AI Analyst Report?
069620 Stock Chart & Stats
$101100.00
-$400.00(-0.39%)
―
--
Day’s Range― - ―
52-Week Range$98,400.00 - $199,400.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)15.75K
Market Cap
₩1.17T
Enterprise Value$2.19T
Total Cash (Recent Filing)₩158.42B
Total Debt (Recent Filing)₩925.02B
Price to Earnings (P/E)6.0
Beta0.10
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.59%
Share Statistics
EPS (TTM)16988.79
Shares Outstanding11,586,575
10 Day Avg. Volume19,160
30 Day Avg. Volume15,749
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.27
P/FCF Ratio-47.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)17,377.79
Revenue Forecast (FY)₩1.62T
Bulls Say, Bears Say
Bulls Say
Revenue And Margin GrowthSustained revenue expansion alongside gross margins above 50% and a sharp recovery in net margin indicates stronger recent operating performance. This supports reinvestment in pharmaceutical development, expands the earnings base, and may improve the company’s ability to compete across domestic and international markets.
Improving Operating Cash FlowThe substantial rebound in operating cash flow shows that the business is converting more of its activity into cash than during 2024. Although free cash flow remains negative, stronger operating inflows provide a better foundation for funding operations and reducing reliance on external financing over coming periods.
Strengthened GovernanceReappointing an independent audit committee member strengthens oversight and brings the company into alignment with amended governance requirements. More robust audit supervision can improve accountability, support regulatory compliance, and provide a durable governance foundation for a pharmaceutical business managing development and commercialization risks.
Bears Say
Rising LeverageDebt has increased materially faster than the earlier balance-sheet base, leaving borrowings at roughly 0.87 times equity in the latest period. This reduces financial flexibility if profitability weakens, increases the importance of successful cash conversion, and can constrain investment or capital-allocation choices.
Persistently Negative Free Cash FlowRepeatedly negative free cash flow indicates that investment and capital spending continue to consume more cash than the business generates after operations. That gap can require additional borrowing or other funding, raising sustainability risk and limiting the company’s ability to finance growth internally.
Earnings VolatilityThe sharp deterioration in profitability during 2024 followed by a strong recovery demonstrates that earnings are not consistently stable. Such volatility can reflect changing costs, product mix, or investment cycles, making future profit conversion harder to predict and increasing sensitivity to operational execution.
Daewoong Pharmaceutical Co., Ltd. News
069620 FAQ
What was Daewoong Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daewoong Pharmaceutical Co., Ltd. lowest stock price was $98400.00 and its highest was $199400.00 in the past 12 months.
What is Daewoong Pharmaceutical Co., Ltd.’s market cap?
Daewoong Pharmaceutical Co., Ltd.’s market cap is ₩1.17T.
When is Daewoong Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Daewoong Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 12 days.
How were Daewoong Pharmaceutical Co., Ltd.’s earnings last quarter?
Daewoong Pharmaceutical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported $2899.861 earnings per share for the quarter.
Is Daewoong Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daewoong Pharmaceutical Co., Ltd.’s price is currently Undervalued.
Does Daewoong Pharmaceutical Co., Ltd. pay dividends?
Daewoong Pharmaceutical Co., Ltd. pays a Annually dividend of $600 which represents an annual dividend yield of 0.59%. See more information on Daewoong Pharmaceutical Co., Ltd. dividends here
What is Daewoong Pharmaceutical Co., Ltd.’s EPS estimate?
Daewoong Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daewoong Pharmaceutical Co., Ltd. have?
Daewoong Pharmaceutical Co., Ltd. has 11,586,575 shares outstanding.
What happened to Daewoong Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daewoong Pharmaceutical Co., Ltd. reported an EPS of $2899.861 in its last earnings report. Following the earnings report the stock price went up 1.054%.
Which hedge fund is a major shareholder of Daewoong Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:069620
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daewoong Pharmaceutical Co., Ltd.
Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its extensive portfolio provides therapeutic solutions across numerous health disciplines, including treatments for central nervous system disorders, endocrine conditions, musculoskeletal ailments, nephrological issues, oncology, cardiovascular diseases, gastrointestinal complaints, and metabolic dysfunctions. The company further offers products addressing viral infections, pain relief, antacids, digestive problems, wound care, and nutritional supplements such as iron and multivitamins. Complementing its pharmaceutical offerings, Daewoong also supplies medical devices, notably COVID-19 PCR and IgG/IgM RDT diagnostic kits, along with viral transport media.
Technical Analysis
JW Pharmaceutical Corporation
―
Chong Kun Dang Holdings Co., Ltd.
―
Bukwang Pharmaceutical Co., Ltd.
―
Celltrion Pharm Inc.
―
Dong-A ST Co., Ltd.
―